Table 4.

Mortality rate ratiosa for selected cancers (New York, 2008–2014)

Aggregated racial/ethnic groupsSelected racial/ethnic subgroups
Non-Hispanic blackAsianHispanicPuerto RicanU.S.-born blackCaribbean-born black
NHWMRR (95% CI)MRR (95% CI)MRR (95% CI)MRR (95% CI)MRR (95% CI)MRR (95% CI)
Males
 Oral11.42 (1.26–1.59)0.97 (0.82–1.16)0.93 (0.81–1.07)1.48 (1.09–2.02)1.93 (1.70–2.19)0.48 (0.34–0.67)
 Esophagus10.80 (0.72–0.88)0.37 (0.31–0.44)0.58 (0.52–0.65)0.87 (0.69–1.09)1.03 (0.92–1.14)0.42 (0.34–0.53)
 Stomach12.20 (2.01–2.41)2.26 (2.03–2.53)1.80 (1.63–1.99)1.85 (1.56–2.18)2.30 (2.07–2.57)1.92 (1.64–2.25)
 Colorectum11.41 (1.32–1.51)0.72 (0.65–0.79)0.94 (0.87–1.01)1.32 (1.09–1.59)1.68 (1.52–1.86)0.90 (0.79–1.03)
 Liverb12.01 (1.59–2.54)2.20 (1.71–2.81)1.72 (1.36–2.16)2.95 (1.89–4.63)2.48 (2.02–3.05)0.73 (0.55–0.96)
  1945–1965 birth cohortc12.54 (2.31–2.79)1.67 (1.46–1.90)2.12 (1.92–2.34)4.27 (3.82–4.78)3.81 (3.45–4.20)0.63 (0.47–0.83)
  Outside birth cohort11.51 (1.17–1.95)2.03 (1.55–2.66)1.51 (1.19–1.93)2.22 (1.92–2.56)1.70 (1.49–1.94)0.72 (0.55–0.95)
 Pancreas11.01 (0.94–1.08)0.55 (0.49–0.62)0.68 (0.63–0.74)0.82 (0.62–1.09)1.23 (1.09–1.39)0.57 (0.47–0.68)
 Lungd11.12 (0.99–1.25)0.59 (0.52–0.67)0.55 (0.49–0.62)0.80 (0.71–0.89)1.49 (1.35–1.65)0.44 (0.39–0.50)
 Prostatee12.74 (2.51–3.00)0.43 (0.37–0.50)1.15 (1.04–1.27)1.29 (1.13–1.48)3.00 (2.67–3.37)2.23 (1.97–2.54)
 Kidney10.78 (0.69–0.89)0.44 (0.36–0.54)0.52 (0.45–0.61)0.71 (0.58–0.86)0.96 (0.83–1.10)0.39 (0.29–0.53)
 Bladder10.62 (0.55–0.69)0.30 (0.24–0.36)0.47 (0.41–0.53)0.61 (0.51–0.72)0.75 (0.67–0.86)0.38 (0.30–0.49)
 NHL10.90 (0.75–1.09)0.56 (0.45–0.70)0.90 (0.75–1.09)1.01 (0.78–1.31)0.93 (0.73–1.19)0.78 (0.58–1.03)
 Myeloma12.06 (1.73–2.44)0.43 (0.32–0.58)1.02 (0.85–1.24)1.03 (0.79–1.36)2.10 (1.70–2.59)2.04 (1.61–2.59)
 Leukemia10.82 (0.73–0.93)0.43 (0.36–0.52)0.61 (0.54–0.70)0.59 (0.47–0.75)0.93 (0.77–1.11)0.69 (0.54–0.87)
 All-sites-combinedf11.21 (1.18–1.24)0.61 (0.59–0.63)0.77 (0.75–0.79)1.05 (0.96–1.16)1.49 (1.36–1.63)0.72 (0.66–0.80)
Females
 Stomach12.15 (1.94–2.39)1.95 (1.68–2.27)1.85 (1.65–2.08)1.85 (1.56–2.20)2.15 (1.90–2.42)2.09 (1.76–2.48)
 Colorectum11.26 (1.19–1.34)0.65 (0.58–0.72)0.81 (0.76–0.88)1.14 (1.01–1.29)1.51 (1.36–1.67)0.93 (0.82–1.07)
 Liverb11.48 (1.26–1.74)1.68 (1.39–2.02)1.82 (1.55–2.12)2.22 (1.74–2.82)1.67 (1.32–2.10)0.96 (0.72–1.28)
  1945–1965 birth cohortc12.18 (1.83–2.60)1.38 (1.05–1.81)2.10 (1.75–2.52)2.97 (2.28–3.87)2.94 (2.34–3.69)0.75 (0.48–1.17)
  Outside birth cohort11.09 (0.95–1.26)1.78 (1.50–2.12)1.64 (1.44–1.86)1.80 (1.50–2.17)1.05 (0.89–1.24)1.08 (0.84–1.38)
 Pancreas11.10 (1.04–1.17)0.61 (0.54–0.68)0.69 (0.64–0.75)0.86 (0.74–0.99)1.36 (1.22–1.53)0.67 (0.58–0.79)
 Lungd10.80 (0.71–0.90)0.40 (0.35–0.46)0.37 (0.33–0.42)0.55 (0.48–0.63)1.15 (1.02–1.29)0.21 (0.18–0.25)
 Breast11.33 (1.27–1.39)0.45 (0.41–0.49)0.69 (0.65–0.74)0.86 (0.79–0.93)1.49 (1.41–1.57)0.97 (0.89–1.05)
  Premenopausalg11.88 (1.69–2.09)0.63 (0.52–0.78)0.79 (0.69–0.91)0.97 (0.79–1.20)2.06 (1.82–2.32)1.47 (1.22–1.77)
  Postmenopausal11.24 (1.18–1.30)0.42 (0.38–0.46)0.68 (0.64–0.72)0.84 (0.77–0.92)1.40 (1.32–1.48)0.90 (0.82–0.98)
 Cervix12.46 (2.21–2.75)0.83 (0.66–1.05)1.60 (1.40–1.82)2.10 (1.76–2.51)2.66 (2.35–3.02)2.01 (1.67–2.41)
 Endometrium12.01 (1.80–2.24)0.42 (0.34–0.52)0.84 (0.74–0.96)0.97 (0.83–1.13)2.15 (1.97–2.36)1.69 (1.49–1.92)
 Ovary10.78 (0.73–0.84)0.56 (0.49–0.63)0.57 (0.52–0.62)0.65 (0.56–0.74)0.83 (0.76–0.91)0.62 (0.54–0.72)
 Kidney10.75 (0.65–0.87)0.47 (0.35–0.62)0.50 (0.41–0.60)0.61 (0.46–0.81)0.97 (0.82–1.15)0.30 (0.20–0.46)
 Bladder10.86 (0.75–0.98)0.45 (0.34–0.59)0.57 (0.48–0.68)0.80 (0.64–1.00)1.01 (0.87–1.17)0.56 (0.42–0.75)
 NHL10.99 (0.77–1.28)0.55 (0.41–0.74)0.82 (0.64–1.06)1.03 (0.74–1.44)0.96 (0.69–1.32)0.84 (0.59–1.19)
 Myeloma11.84 (1.67–2.04)0.38 (0.28–0.52)0.96 (0.83–1.10)1.05 (0.85–1.29)1.96 (1.74–2.21)1.64 (1.38–1.96)
 Leukemia10.68 (0.61–0.76)0.46 (0.38–0.56)0.70 (0.63–0.79)0.80 (0.68–0.95)0.71 (0.62–0.81)0.52 (0.42–0.64)
 All-sites-combinedf11.14 (1.05–1.23)0.54 (0.50–0.59)0.67 (0.62–0.73)0.86 (0.78–0.95)1.33 (1.22–1.46)0.74 (0.67–0.81)
  • Abbreviations: CUP, cancers of unknown primary; HCV, Hepatitis C virus; NHL, non-Hodgkin lymphoma; NHW, non-Hispanic white.

  • aMRRs derived from negative binomial regression including ages 35+ for all cancers, prostate 45+.

  • bIncludes intrahepatic bile duct.

  • cHigh HCV prevalence birth cohort (1945–1965).

  • dIncludes bronchus.

  • eIncludes ages 45+.

  • fAll sites combined includes those listed as well as those not listed here.

  • gCutoff of age 50 used to approximate pre- and postmenopausal status.